Concurrent Pilot Studies in Giant Cell Arteritis and Takayasu's Arteritis to Examine the Safety, Efficacy, and Immunologic Effects of Abatacept (CTLA4-Ig) in Large Vessel Vasculitis

Trial Profile

Concurrent Pilot Studies in Giant Cell Arteritis and Takayasu's Arteritis to Examine the Safety, Efficacy, and Immunologic Effects of Abatacept (CTLA4-Ig) in Large Vessel Vasculitis

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Giant cell arteritis; Takayasu syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jan 2017 New trial record
    • 30 Jan 2017 Results of patients with giant cell arteritis (n=49) published in the Arthritis and Rheumatology
    • 30 Jan 2017 Results of patients with Takayasu's arteritis (n=34) published in the Arthritis and Rheumatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top